Download PDF
CC BY-NC-ND 4.0 · Semin Liver Dis 2021; 41(04): 495-506
DOI: 10.1055/s-0041-1732319
Review Article

Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review

Xinpei Gu
1   Department of Human Anatomy, Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, China
,
Qin Lu
2   Department of Prescription Science, School of Basic Medical Sciences, Hebei University of Chinese Medicine, Shijiazhuang, China
,
Chengcheng Zhang
3   Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
,
Zhewei Tang
3   Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
,
Liuxi Chu
4   Institute of Child Development and Education, School of Biological Sciences and Medical Engineering, Southeast University, Nanjing, China
› Author Affiliations Funding National Natural Science Foundation of China (81904129), the College Student Innovation Funds Project for the Hebei University of Chinese Medicine (31800952, 202014432203), the Fundamental Research Funds for the Southeast University (3218006405, 2242019s10024) sponsored this study.
› Further Information
   Permissions and Reprints

Abstract

The human gut harbors a dense and highly diverse microbiota of approximately 1,000 bacterial species. The interaction between the host and gut bacteria strongly influences human health. Numerous evidence suggest that intestinal flora imbalance is closely associated with the development and treatment of liver diseases, including acute liver injury and chronic liver diseases (cirrhosis, autoimmune liver disease, and fatty liver). Therefore, regulating the gut microbiota is expected to be a new method for the adjuvant treatment of liver diseases. Fecal microbiota transplantation (FMT) is defined as the transplantation of gut microbiota from healthy donors to sick patients via the upper or lower gastrointestinal route to restore the normal intestinal balance. In this study, we briefly review the current research on the gut microbiota and its link to liver diseases and then summarize the evidence to elucidate the clinical application and development of FMT in liver disease treatment.

Keywords

gut microbiota - microbiota imbalance - liver diseases - microbiome

Authors' Contributions

X.G. and L.C. designed the concept of the study. Q.L., C.Z., and X.G. wrote the first draft of the manuscript. L.C. and Z.T. edited the subsequent versions of the manuscript.




Publication History

Article published online:
14 July 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Medini D, Serruto D, Parkhill J. et al. Microbiology in the post-genomic era. Nat Rev Microbiol 2008; 6 (06) 419-430
    CrossrefPubMedGoogle Scholar
  • 2 Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell 2012; 148 (06) 1258-1270
    CrossrefPubMedGoogle Scholar
  • 3 Palacios T, Vitetta L, Coulson S. et al. Targeting the intestinal microbiota to prevent type 2 diabetes and enhance the effect of metformin on glycaemia: a randomised controlled pilot study. Nutrients 2020; 12 (07) 12
    CrossrefPubMedGoogle Scholar
  • 4 van Wietmarschen HA, Busch M, van Oostveen A, Pot G, Jong MC. Probiotics use for antibiotic-associated diarrhea: a pragmatic participatory evaluation in nursing homes. BMC Gastroenterol 2020; 20 (01) 151
    CrossrefPubMedGoogle Scholar
  • 5 Bakken JS, Borody T, Brandt LJ. et al; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9 (12) 1044-1049
    CrossrefPubMedGoogle Scholar
  • 6 Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res 2017; 179: 49-59
    CrossrefPubMedGoogle Scholar
  • 7 Hawkins KG, Casolaro C, Brown JA, Edwards DA, Wikswo JP. The microbiome and the gut-liver-brain axis for central nervous system clinical pharmacology: challenges in specifying and integrating in vitro and in silico models. Clin Pharmacol Ther 2020; 108 (05) 929-948
    CrossrefPubMedGoogle Scholar
  • 8 Bajaj JS, Kassam Z, Fagan A. et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 2017; 66 (06) 1727-1738
    CrossrefPubMedGoogle Scholar
  • 9 Mehta R, Kabrawala M, Nandwani S. et al. Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy—a case series. Indian J Gastroenterol 2018; 37 (06) 559-562
    CrossrefPubMedGoogle Scholar
  • 10 Le Roy T, Llopis M, Lepage P. et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013; 62 (12) 1787-1794
    CrossrefPubMedGoogle Scholar
  • 11 Gomez-Hurtado I, Gallego-Duran R, Zapater P. et al. Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. Liver Int 2020; 40 (09) 2182-2193
    CrossrefPubMedGoogle Scholar
  • 12 Frank DN, Zhu W, Sartor RB, Li E. Investigating the biological and clinical significance of human dysbioses. Trends Microbiol 2011; 19 (09) 427-434
    CrossrefPubMedGoogle Scholar
  • 13 Boursier J, Diehl AM. Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog 2015; 11 (01) e1004559
    CrossrefPubMedGoogle Scholar
  • 14 Llopis M, Cassard AM, Wrzosek L. et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 2016; 65 (05) 830-839
    CrossrefPubMedGoogle Scholar
  • 15 Furukawa M, Moriya K, Nakayama J. et al. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatol Res 2020; 50 (07) 840-852
    CrossrefPubMedGoogle Scholar
  • 16 Wu G, Win S, Than TA, Chen P, Kaplowitz N. Gut microbiota and liver injury (I)-acute liver injury. Adv Exp Med Biol 2020; 1238: 23-37
    CrossrefPubMedGoogle Scholar
  • 17 Wang Y, Pan CQ, Xing H. Advances in gut microbiota of viral hepatitis cirrhosis. BioMed Res Int 2019; 2019: 9726786
    PubMedGoogle Scholar
  • 18 Alonso C, Fernández-Ramos D, Varela-Rey M. et al. Metabolomic identification of subtypes of nonalcoholic steatohepatitis. Gastroenterology 2017; 152 (06) 1449-1461.e7
    CrossrefPubMedGoogle Scholar
  • 19 Kaikkonen JE, Würtz P, Suomela E. et al. Metabolic profiling of fatty liver in young and middle-aged adults: cross-sectional and prospective analyses of the Young Finns Study. Hepatology 2017; 65 (02) 491-500
    CrossrefPubMedGoogle Scholar
  • 20 Loomba R, Seguritan V, Li W. et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2017; 25 (05) 1054-1062.e5
    CrossrefPubMedGoogle Scholar
  • 21 Boursier J, Mueller O, Barret M. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016; 63 (03) 764-775
    CrossrefPubMedGoogle Scholar
  • 22 Oh TG, Kim SM, Caussy C. et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab 2020; 32 (05) 878-888.e6
    CrossrefPubMedGoogle Scholar
  • 23 Oh TG, Kim SM, Atkins AR. et al. Proton pump inhibitor use status does not modify the microbiome signature for cirrhosis. Cell Metab 2021; 33 (03) 457
    CrossrefPubMedGoogle Scholar
  • 24 Aron-Wisnewsky J, Vigliotti C, Witjes J. et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020; 17 (05) 279-297
    CrossrefPubMedGoogle Scholar
  • 25 Adams LA, Wang Z, Liddle C. et al. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2020; 40 (06) 1356-1365
    CrossrefPubMedGoogle Scholar
  • 26 Ghoshal UC, Goel A, Quigley EMM. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: an emerging paradigm. Indian J Gastroenterol 2020; 39 (01) 9-21
    CrossrefPubMedGoogle Scholar
  • 27 Guohong-Liu, Qingxi-Zhao, Hongyun-Wei. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. Ann Hepatol 2019; 18 (06) 796-803
    CrossrefPubMedGoogle Scholar
  • 28 Shah A, Macdonald GA, Morrison M, Holtmann G. Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: a conceptional framework. Am J Gastroenterol 2020; 115 (06) 814-822
    CrossrefPubMedGoogle Scholar
  • 29 Buness JG, Ali AH, Tabibian JH, Buness CW, Cox KL, Lindor KD. Potential association of doxycycline with the onset of primary sclerosing cholangitis: a case series. Am J Ther 2019; 26 (04) e551-e557 DOI: 10.1097/MJT.0000000000001065.
    CrossrefPubMedGoogle Scholar
  • 30 Liwinski T, Zenouzi R, John C. et al. Alterations of the bile microbiome in primary sclerosing cholangitis. Gut 2020; 69 (04) 665-672
    CrossrefPubMedGoogle Scholar
  • 31 Chen Z, Xie Y, Zhou F. et al. Featured gut microbiomes associated with the progression of chronic hepatitis B disease. Front Microbiol 2020; 11: 383
    CrossrefPubMedGoogle Scholar
  • 32 Beraza N. Fibrosis and the intestinal microbiome; a focus on chronic liver disease. Curr Opin Pharmacol 2019; 49: 76-81
    CrossrefPubMedGoogle Scholar
  • 33 Jia W, Rajani C, Kaddurah-Daouk R, Li H. Expert insights: the potential role of the gut microbiome-bile acid-brain axis in the development and progression of Alzheimer's disease and hepatic encephalopathy. Med Res Rev 2020; 40 (04) 1496-1507
    CrossrefPubMedGoogle Scholar
  • 34 Liu R, Kang JD, Sartor RB. et al. Neuroinflammation in murine cirrhosis is dependent on the gut microbiome and is attenuated by fecal transplant. Hepatology 2020; 71 (02) 611-626
    CrossrefPubMedGoogle Scholar
  • 35 Bajaj JS, Fagan A, White MB. et al. Specific gut and salivary microbiota patterns are linked with different cognitive testing strategies in minimal hepatic encephalopathy. Am J Gastroenterol 2019; 114 (07) 1080-1090
    CrossrefPubMedGoogle Scholar
  • 36 Acharya C, Bajaj JS. Current management of hepatic encephalopathy. Am J Gastroenterol 2018; 113 (11) 1600-1612
    CrossrefPubMedGoogle Scholar
  • 37 Bajaj JS, Ridlon JM, Hylemon PB. et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012; 302 (01) G168-G175
    CrossrefPubMedGoogle Scholar
  • 38 Lin RS, Lee FY, Lee SD. et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995; 22 (02) 165-172
    CrossrefPubMedGoogle Scholar
  • 39 Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol 2021; 18 (01) 4-17
    CrossrefPubMedGoogle Scholar
  • 40 Cesaro C, Tiso A, Del Prete A. et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis 2011; 43 (06) 431-438
    CrossrefPubMedGoogle Scholar
  • 41 Mu J, Tan F, Zhou X, Zhao X. Lactobacillus fermentum CQPC06 in naturally fermented pickles prevents non-alcoholic fatty liver disease by stabilizing the gut-liver axis in mice. Food Funct 2020; 11 (10) 8707-8723
    CrossrefPubMedGoogle Scholar
  • 42 Acharya C, Bajaj JS. Altered microbiome in patients with cirrhosis and complications. Clin Gastroenterol Hepatol 2019; 17 (02) 307-321
    CrossrefPubMedGoogle Scholar
  • 43 Lee NY, Suk KT. The role of the gut microbiome in liver cirrhosis treatment. Int J Mol Sci 2020; 22 (01) 16
    CrossrefPubMedGoogle Scholar
  • 44 Kang DJ, Betrapally NS, Ghosh SA. et al. Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. Hepatology 2016; 64 (04) 1232-1248
    CrossrefPubMedGoogle Scholar
  • 45 Caussy C, Hsu C, Lo M-T. et al; Genetics of NAFLD in Twins Consortium. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology 2018; 68 (03) 918-932
    CrossrefPubMedGoogle Scholar
  • 46 Trapecar M, Communal C, Velazquez J. et al. Gut-liver physiomimetics reveal paradoxical modulation of IBD-related inflammation by short-chain fatty acids. Cell Syst 2020; 10 (03) 223-239.e9
    CrossrefPubMedGoogle Scholar
  • 47 Saeedi BJ, Liu KH, Owens JA. et al. Gut-resident lactobacilli activate hepatic Nrf2 and protect against oxidative liver injury. Cell Metab 2020; 31 (05) 956-968.e5
    CrossrefPubMedGoogle Scholar
  • 48 Woodhouse CA, Patel VC, Goldenberg S. et al. PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial. BMJ Open 2019; 9 (02) e023518
    CrossrefPubMedGoogle Scholar
  • 49 Bajaj JS, Kakiyama G, Savidge T. et al. Antibiotic-associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant. Hepatology 2018; 68 (04) 1549-1558
    CrossrefPubMedGoogle Scholar
  • 50 Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am J Gastroenterol 2012; 107 (11) 1755 , author reply 1755–1756
    CrossrefPubMedGoogle Scholar
  • 51 Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44 (05) 854-859
    PubMedGoogle Scholar
  • 52 Schwan A, Sjölin S, Trottestam U, Aronsson B. Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet 1983; 2 (8354): 845
    CrossrefPubMedGoogle Scholar
  • 53 Kelly CR, Kahn S, Kashyap P. et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 2015; 149 (01) 223-237
    CrossrefPubMedGoogle Scholar
  • 54 Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014; 312 (17) 1772-1778
    CrossrefPubMedGoogle Scholar
  • 55 Gustafsson A, Berstad A, Lund-Tønnesen S, Midtvedt T, Norin E. The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhoea. Scand J Gastroenterol 1999; 34 (06) 580-586
    CrossrefPubMedGoogle Scholar
  • 56 Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000; 95 (11) 3283-3285
    PubMedGoogle Scholar
  • 57 Yin G, Li JF, Sun YF. et al. [Fecal microbiota transplantation as a novel therapy for severe psoriasis]. Zhonghua Nei Ke Za Zhi 2019; 58 (10) 782-785
    PubMedGoogle Scholar
  • 58 Liu J, Miyake H, Zhu H. et al. Fecal microbiota transplantation by enema reduces intestinal injury in experimental necrotizing enterocolitis. J Pediatr Surg 2020; 55 (06) 1094-1098
    CrossrefPubMedGoogle Scholar
  • 59 Cheng Y-W, Alhaffar D, Saha S. et al. Fecal microbiota transplantation is safe and effective in patients with Clostridioides difficile infection and cirrhosis. Clin Gastroenterol Hepatol 2020; 18 (08) 1874-1881 DOI: 10.1016/j.cgh.2020.06.051.
    CrossrefPubMedGoogle Scholar
  • 60 Craven L, Rahman A, Nair Parvathy S. et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol 2020; 115 (07) 1055-1065
    CrossrefPubMedGoogle Scholar
  • 61 Kao D, Roach B, Park H. et al. Fecal microbiota transplantation in the management of hepatic encephalopathy. Hepatology 2016; 63 (01) 339-340
    CrossrefPubMedGoogle Scholar
  • 62 Meighani A, Alimirah M, Ramesh M, Salgia R. Fecal microbiota transplantation for Clostridioides difficile infection in patients with chronic liver disease. Int J Hepatol 2020; 2020: 1874570
    CrossrefPubMedGoogle Scholar
  • 63 Philips CA, Phadke N, Ganesan K, Augustine P. Healthy donor faecal transplant for corticosteroid non-responsive severe alcoholic hepatitis. BMJ Case Rep 2017; 2017: bcr-2017–222310
    CrossrefPubMedGoogle Scholar
  • 64 Ren YD, Ye ZS, Yang LZ. et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology 2017; 65 (05) 1765-1768
    CrossrefPubMedGoogle Scholar
  • 65 Surawicz CM, Brandt LJ, Binion DG. et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108 (04) 478-498 , quiz 499
    CrossrefPubMedGoogle Scholar
  • 66 Vaughn BP, Rank KM, Khoruts A. Fecal microbiota transplantation: current status in treatment of GI and liver disease. Clin Gastroenterol Hepatol 2019; 17 (02) 353-361
    CrossrefPubMedGoogle Scholar
  • 67 Vendrik KEW, Ooijevaar RE, de Jong PRC. et al. Fecal microbiota transplantation in neurological disorders. Front Cell Infect Microbiol 2020; 10: 98
    CrossrefPubMedGoogle Scholar
  • 68 Gerussi A, Lucà M, Cristoferi L. et al. New therapeutic targets in autoimmune cholangiopathies. Front Med (Lausanne) 2020; 7: 117
    CrossrefPubMedGoogle Scholar
  • 69 Mahajan R, Midha V, Singh A. et al. Incidental benefits after fecal microbiota transplant for ulcerative colitis. Intest Res 2020; 18 (03) 337-340
    CrossrefPubMedGoogle Scholar
  • 70 Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48 (08) 693-702
    CrossrefPubMedGoogle Scholar
  • 71 DeFilipp Z, Bloom PP, Torres Soto M. et al. Drug-Resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 2019; 381 (21) 2043-2050
    CrossrefPubMedGoogle Scholar
  • 72 Moayyedi P, Surette MG, Kim PT. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015; 149 (01) 102-109.e6
    CrossrefPubMedGoogle Scholar
  • 73 Yu EW, Gao L, Stastka P. et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: the FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med 2020; 17 (03) e1003051
    CrossrefPubMedGoogle Scholar
  • 74 Dailey FE, Turse EP, Daglilar E, Tahan V. The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications. Curr Opin Pharmacol 2019; 49: 29-33
    CrossrefPubMedGoogle Scholar
  • 75 Bajaj JS, Salzman NH, Acharya C. et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial. Hepatology 2019; 70 (05) 1690-1703
    CrossrefPubMedGoogle Scholar
  • 76 Wang WW, Zhang Y, Huang XB, You N, Zheng L, Li J. Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-induced acute hepatic dysfunction. World J Gastroenterol 2017; 23 (38) 6983-6994
    CrossrefPubMedGoogle Scholar
  • 77 Lachar J, Bajaj JS. Changes in the microbiome in cirrhosis and relationship to complications: hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis. Semin Liver Dis 2016; 36 (04) 327-330
    Article in Thieme ConnectPubMedGoogle Scholar
  • 78 Santiago A, Pozuelo M, Poca M. et al. Alteration of the serum microbiome composition in cirrhotic patients with ascites. Sci Rep 2016; 6: 25001
    CrossrefPubMedGoogle Scholar
  • 79 Tabibian JH, O'Hara SP, Trussoni CE. et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology 2016; 63 (01) 185-196
    CrossrefPubMedGoogle Scholar
  • 80 Bajaj JS, Hays RA. Manipulation of the gut-liver axis using microbiome restoration therapy in primary sclerosing cholangitis. Am J Gastroenterol 2019; 114 (07) 1027-1029
    CrossrefPubMedGoogle Scholar
  • 81 Philips CA, Augustine P, Phadke N. Healthy donor fecal microbiota transplantation for recurrent bacterial cholangitis in primary sclerosing cholangitis—a single case report. J Clin Transl Hepatol 2018; 6 (04) 438-441
    PubMedGoogle Scholar
  • 82 Allegretti JR, Kassam Z, Carrellas M. et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol 2019; 114 (07) 1071-1079
    CrossrefPubMedGoogle Scholar
  • 83 Philips CA, Pande A, Shasthry SM. et al. healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol 2017; 15 (04) 600-602
    CrossrefPubMedGoogle Scholar
  • 84 Philips CA, Phadke N, Ganesan K, Ranade S, Augustine P. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. Indian J Gastroenterol 2018; 37 (03) 215-225
    CrossrefPubMedGoogle Scholar
  • 85 Jiang L, Lang SJ, Duan Y. et al. Intestinal virome in patients with alcoholic hepatitis. Hepatology 2020; 72 (06) 2182-2196
    CrossrefPubMedGoogle Scholar
  • 86 Lang S, Duan Y, Liu J. et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology 2020; 71 (02) 522-538
    CrossrefPubMedGoogle Scholar
  • 87 Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr 2017; 64 (03) 413-417
    CrossrefPubMedGoogle Scholar
  • 88 Zhou D, Pan Q, Shen F. et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep 2017; 7 (01) 1529
    CrossrefPubMedGoogle Scholar
  • 89 Ferrere G, Wrzosek L, Cailleux F. et al. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. J Hepatol 2017; 66 (04) 806-815
    CrossrefPubMedGoogle Scholar
  • 90 Zhuge A, Li B, Yuan Y. et al. Lactobacillus salivarius LI01 encapsulated in alginate-pectin microgels ameliorates D-galactosamine-induced acute liver injury in rats. Appl Microbiol Biotechnol 2020; 104 (17) 7437-7455
    CrossrefPubMedGoogle Scholar
  • 91 Chauhan A, Kumar R, Sharma S. et al. Fecal microbiota transplantation in hepatitis B e antigen-positive chronic hepatitis B patients: a pilot study. Dig Dis Sci 2021; 66 (03) 873-880
    CrossrefPubMedGoogle Scholar
  • 92 Ronis MJ, Mercer KE, Shankar K. et al. Potential role of gut microbiota, the proto-oncogene PIKE (Agap2) and cytochrome P450 CYP2W1 in promotion of liver cancer by alcoholic and nonalcoholic fatty liver disease and protection by dietary soy protein. Chem Biol Interact 2020; 325: 109131
    CrossrefPubMedGoogle Scholar
  • 93 Behzadi E, Mahmoodzadeh Hosseini H, Imani Fooladi AA. The inhibitory impacts of Lactobacillus rhamnosus GG-derived extracellular vesicles on the growth of hepatic cancer cells. Microb Pathog 2017; 110: 1-6
    CrossrefPubMedGoogle Scholar
  • 94 Chu L, Huang Y, Xu Y. et al. An LC-APCI+-MS/MS-based method for determining the concentration of neurosteroids in the brain of male mice with different gut microbiota. Journal of Neuroscience Mehods 2021; 360: 109268
    CrossrefPubMedGoogle Scholar
  • 95 Chu LX, Li N, Deng J. et al. LC-APCI+-MS/MS method for the analysis of ten hormones and two endocannabinoids in plasma and hair from the mice with different gut microbiota. J Pharm Biomed Anal 2020; 185: 113223
    CrossrefPubMedGoogle Scholar